Cell therapy innovators and CDMOs can benefit from this collaboration by integrating Thermo Fisher's top-notch solutions while enjoying the advantages of automation, such as cost reduction and increased throughput. Multiply Labs recently demonstrated that automated and manual cell expansion processes are statistically equivalent. This implies that manufacturers can automate their current cell expansion protocols with minimal alterations and reduced regulatory risk. Fred Parietti, PhD, Co-Founder and CEO of Multiply Labs, expressed enthusiasm about the collaboration's potential impact on cell therapy manufacturing. "The goal is to establish a seamlessly automated, plug-and-play process that positively influences patient care. The ongoing partnership with Thermo Fisher plays a crucial role in turning this vision into reality, advancing the realization of cell therapy for the benefit of patients."